Alnylam Pharmaceuticals ALNY Enterprise value

Enterprise value at other companies

Ionis PharmaceuticalsIONS

$13.02B+91.2%

Arrowhead ResearchARWR

$8.7B+418%

PTC TherapeuticsPTCT

$5.2B+77.3%

Assembly BiosciencesASMB

$411.56M+702%

Arbutus Biopharma CorporationABUS

$856.58M+35.5%

Wave Life SciencesWVE

$793.44M-9.4%

FAQ

What is Alnylam Pharmaceuticals's enterprise value?

Alnylam Pharmaceuticals (ALNY) reported enterprise value of $38.74B in Q2 2026.

How has Alnylam Pharmaceuticals's enterprise value changed year-over-year?

Alnylam Pharmaceuticals's enterprise value decreased by 6.7% year-over-year, from $41.53B to $38.74B.

What is the long-term trend for Alnylam Pharmaceuticals's enterprise value?

Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's enterprise value has grown at a 26.9% compound annual growth rate (CAGR), from $15.57B to $51.15B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.